226 related articles for article (PubMed ID: 11264179)
41. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
[TBL] [Abstract][Full Text] [Related]
42. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
[TBL] [Abstract][Full Text] [Related]
43. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group.
Brisco MJ; Condon J; Hughes E; Neoh SH; Nicholson I; Sykes PJ; Tauro G; Ekert H; Waters K; Toogood I
Leukemia; 1993 Oct; 7(10):1514-20. PubMed ID: 8412313
[TBL] [Abstract][Full Text] [Related]
45. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.
Uckun FM; Kersey JH; Haake R; Weisdorf D; Ramsay NK
Blood; 1992 Feb; 79(4):1094-104. PubMed ID: 1531306
[TBL] [Abstract][Full Text] [Related]
46. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.
Coustan-Smith E; Sancho J; Behm FG; Hancock ML; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Pui CH; Campana D
Blood; 2002 Jul; 100(1):52-8. PubMed ID: 12070008
[TBL] [Abstract][Full Text] [Related]
47. B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
Mikhailova E; Itov A; Zerkalenkova E; Roumiantseva J; Olshanskaya Y; Karachunskiy A; Novichkova G; Maschan M; Popov A
Cytometry B Clin Cytom; 2022 Sep; 102(5):353-359. PubMed ID: 35796438
[TBL] [Abstract][Full Text] [Related]
48. CD10 and CD19 fluorescence intensity of B-cell precursors in normal and leukemic bone marrow. Clinical characterization of CD10(+strong) and CD10(+weak) common acute lymphoblastic leukemia.
Rego EM; Tone LG; Garcia AB; Falcão RP
Leuk Res; 1999 May; 23(5):441-50. PubMed ID: 10374858
[TBL] [Abstract][Full Text] [Related]
49. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
[TBL] [Abstract][Full Text] [Related]
50. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
[TBL] [Abstract][Full Text] [Related]
51. Genetic changes: relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia.
Cole-Sinclair MF; Foroni L; Hoffbrand AV
Baillieres Clin Haematol; 1994 Jun; 7(2):183-233. PubMed ID: 7803899
[TBL] [Abstract][Full Text] [Related]
52. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
53. CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia.
Rhein P; Mitlohner R; Basso G; Gaipa G; Dworzak MN; Kirschner-Schwabe R; Hagemeier C; Stanulla M; Schrappe M; Ludwig WD; Karawajew L; Ratei R
Blood; 2010 May; 115(18):3763-71. PubMed ID: 20228269
[TBL] [Abstract][Full Text] [Related]
54. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
55. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract][Full Text] [Related]
56. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse.
Biondi A; Yokota S; Hansen-Hagge TE; Rossi V; Giudici G; Maglia O; Basso G; Tell C; Masera G; Bartram CR
Leukemia; 1992 Apr; 6(4):282-8. PubMed ID: 1316978
[TBL] [Abstract][Full Text] [Related]
57. Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
Ruano D; Diaz MA; Tutor O; Garcia-Sanchez F; Martinez P; Madero L
Haematologica; 2000 Aug; 85(8):877-8. PubMed ID: 10942942
[No Abstract] [Full Text] [Related]
58. New markers for minimal residual disease detection in acute lymphoblastic leukemia.
Coustan-Smith E; Song G; Clark C; Key L; Liu P; Mehrpooya M; Stow P; Su X; Shurtleff S; Pui CH; Downing JR; Campana D
Blood; 2011 Jun; 117(23):6267-76. PubMed ID: 21487112
[TBL] [Abstract][Full Text] [Related]
59. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease.
Dworzak MN; Fröschl G; Printz D; Zen LD; Gaipa G; Ratei R; Basso G; Biondi A; Ludwig WD; Gadner H
Leukemia; 2004 Apr; 18(4):703-8. PubMed ID: 14961034
[TBL] [Abstract][Full Text] [Related]
60. Immunophenotype of normal and leukemic bone marrow B-precursors in a Brazilian population. A comparative analysis by quantitative fluorescence cytometry.
Rego EM; Garcia AB; Carneiro JJ; Falcão RP
Braz J Med Biol Res; 2001 Feb; 34(2):183-94. PubMed ID: 11175493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]